New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of ...
– exoIL-12 has demonstrated tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Novel engineered exosome therapeutic candidate currently in Phase 1 clinical trial with data …